Last Updated:
3:27 pm
Friday, June 20, 2025
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
asx-agn
Market Cap
AU$89.02M
Volume
66807
Open
0.73
AU$
High
0.73
AU$
Low
0.70
AU$
Shares On Issue
128M
52 Week Low
0.595
AU$
52 Week High
0.985
AU$
Website
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved